Development and validation of a simple and rapid method for hepatitis C virus genotyping based on one‑step RT‑qPCR

Yang,Xinyun; Ding,Ting; Huang,Haifeng; Xu,Yang; Yu,Jian; Chen,Zhanguo

doi:10.3892/etm.2020.8912

Development and validation of a simple and rapid method for hepatitis C virus genotyping based on one‑step RT‑qPCR

Authors:
- Xinyun Yang
- Ting Ding
- Haifeng Huang
- Yang Xu
- Jian Yu
- Zhanguo Chen
View Affiliations

Affiliations: Department of Laboratory Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China, Triplex International Biosciences (China) Co., Ltd., Xiamen, Fujian 361000, P.R. China, Department of First Generation Sequencing, Hangzhou DiAn Medical Laboratory, Hangzhou, Zhejiang 310030, P.R. China
Published online on: June 19, 2020 https://doi.org/10.3892/etm.2020.8912
Pages: 2284-2290

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatitis C virus (HCV) infections caused by different subtypes require different treatments; therefore, rapid and cost‑effective genotyping methods for the diagnosis of HCV are greatly needed. In the present study, a new method to diagnose HCV subtypes that depends on a one‑step quantitative reverse transcription PCR (RT‑qPCR) and TaqMan fluorescence probe technique is described. Five pairs of primers and five probes were designed, which were able to detect five genotypes in three reaction tubes. One reaction was used to detect the 1b subtype, one was used to detect the 2a and 6a subtypes, and the other was used to detect the 3a and 3b subtypes. Rigorous performance validation was implemented for five aspects: Precision, sensitivity, accuracy, specificity and anti‑interference. The HCV subtype that infected 289 patients was evaluated in the present study via RT‑qPCR and verified by sequencing. The results revealed that the 1b subtype accounted for 45% of infections, the 2a subtype accounted for 9% of infections, the 3a subtype accounted for 13% of infections, the 3b subtype accounted for 18% of infections, and the 6a subtype accounted for 15% of infections. The analytical sensitivity for the detection of each of the five HCV subtypes was 1,000 IU/ml. The new method performed well in the performance validation mentioned above, indicating its effectiveness as a HCV genotyping method. RT‑qPCR has mitigated some of the former challenges of existing HCV genotyping methods, including the time commitment, expense, and inaccuracy of such methods. The performance validation of this new method showed that RT‑qPCR is reliable enough to be widely applied in China for HCV genotyping.

View Figures

View References

1	Lavanchy D: Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 17:107–115. 2011.PubMed/NCBI View Article : Google Scholar
2	World Health Organization: Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection: Updated Version, Geneva, 2016. https://www.who.int/hepatitis/publications/hep-c-guidelines-2016_170.png.
3	Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P, et al: The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat. 21 (Suppl 1)(S34-S59)2014.PubMed/NCBI View Article : Google Scholar
4	Petruzziello A, Marigliano S, Loquercio G, Cozzolino A and Cacciapuoti C: Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 22:7824–7840. 2016.PubMed/NCBI View Article : Google Scholar
5	Polaris Observatory HCV Collaborators; Blach S, Zeuzem S, Manns M, Altraif I, Duberg AS, Muljono DH, Waked I, Alavian SM, Lee MH, et al: Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol Hepatol. 2:161–176. 2017.PubMed/NCBI View Article : Google Scholar
6	Tong YQ, Liu B, Liu H, Zheng HY, Gu J, Liu H, Song EJ, Song C and Li Y: Accurate genotyping of hepatitis C virus through nucleotide sequencing and identification of new HCV subtypes in China population. Clin Microbiol Infect. 21(874.e9-e847.e21)2015.PubMed/NCBI View Article : Google Scholar
7	Grebely J and Dore GJ: What is killing people with hepatitis C virus infection? Semin Liver Dis. 31:331–339. 2011.PubMed/NCBI View Article : Google Scholar
8	Schinazi R, Halfon P, Marcellin P and Asselah T: HCV direct-acting antiviral agents: The best interferon-free combinations. Liver Int. 34 (Suppl 1)(S69-S78)2014.PubMed/NCBI View Article : Google Scholar
9	De Clercq E: Current race in the development of DAAs (direct-acting antivirals) against HCV. Biochem Pharmacol. 89:441–452. 2014.PubMed/NCBI View Article : Google Scholar
10	European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 69:461–511. 2018.
11	Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N and Younossi Z: Hepatitis C virus infection. Nat Rev Dis Primers. 3(17006)2017.PubMed/NCBI View Article : Google Scholar
12	European Association for the Study of the Liver. EASL recommendations on treatment of Hepatitis C 2016. J Hepatol. 66:153–194. 2017.
13	Yang R and Wei L: Profile of the VERSANT HCV genotype 2.0 assay. Expert Rev Mol Diagn. 18:995–1004. 2018.PubMed/NCBI View Article : Google Scholar
14	Verbeeck J, Stanley MJ, Shieh J, Celis L, Huyck E, Wollants E, Morimoto J, Farrior A, Sablon E, Jankowski-Hennig M, et al: Evaluation of versant Hepatitis C virus genotype assay (LiPA) 2.0. J Clin Microbiol. 46:1901–1906. 2008.PubMed/NCBI View Article : Google Scholar
15	Gryadunov D, Nicot F, Dubois M, Mikhailovich V, Zasedatelev A and Izopet J: Hepatitis C virus genotyping using an oligonucleotide microarray based on the NS5B sequence. J Clin Microbiol. 48:3910–3917. 2010.PubMed/NCBI View Article : Google Scholar
16	Rodriguez-Frias F, Nieto-Aponte L, Gregori J, Garcia-Cehic D, Casillas R, Tabernero D, Homs M, Blasi M, Vila M, Chen Q, et al: High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping. Clin Microbiol Infect. 23(775.e1-775.e6)2017.PubMed/NCBI View Article : Google Scholar
17	Soria ME, Gregori J, Chen Q, García-Cehic D, Llorens M, de Ávila AI, Beach NM, Domingo E, Rodríguez-Frías F, Buti M, et al: Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus. BMC Infect Dis. 18(446)2018.PubMed/NCBI View Article : Google Scholar
18	Roy F, Mendoza L, Hiebert J, McNall RJ, Bankamp B, Connolly S, Lüdde A, Friedrich N, Mankertz A, Rota PA and Severini A: Rapid identification of measles virus vaccine genotype by real-time PCR. J Clin Microbiol. 55:735–743. 2017.PubMed/NCBI View Article : Google Scholar
19	Warkad SD, Nimse SB, Song KS and Kim T: HCV detection, discrimination, and genotyping technologies. Sensors (Basel). 18(pii: E3423)2018.PubMed/NCBI View Article : Google Scholar
20	Nyan DC and Swinson KL: A method for rapid detection and genotype identification of hepatitis C virus 1-6 by one-step reverse transcription loop-mediated isothermal amplification. Int J Infect Dis. 43:30–36. 2016.PubMed/NCBI View Article : Google Scholar
21	Zhang Y, Chen LM and He M: Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution. Virol J. 14(41)2017.PubMed/NCBI View Article : Google Scholar
22	Chen Y, Yu C, Yin X, Guo X, Wu S and Hou J: Hepatitis C virus genotypes and subtypes circulating in Mainland China. Emerg Microbes Infect. 6(e95)2017.PubMed/NCBI View Article : Google Scholar